1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Asaf Danziger

No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700


Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
Nov 23, 2022 13:00pm

Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 9:30 a.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation

NovoCure Limited (NASDAQ:NVCR) Will Likely Reach 200.00 USD!
Nov 19, 2022 15:30pm

NovoCure Limited (NASDAQ:NVCR) shares, rose in value on Friday, 11/18/22, with the stock price up by 0.13% to the previous day’s close as strong demand from buyers drove the stock to $77.49. Actively observing the price movement in the last trading, the stock closed the session at $77.39, falling within a range of $75.88 and … NovoCure Limited (NASDAQ:NVCR) Will Likely Reach 200.00 USD! Read More »

Source:Stocks Register
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Nov 17, 2022 13:00pm

Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20 in Tampa. The presentations cover a broad range of topics, including TTFields’ multimodal mechanism of action, safety and tolerability, and health economics and outcomes research (HEOR). New research

Was anything positive for NovoCure Limited (NVCR) stock last session?
Nov 11, 2022 14:32pm

A share of NovoCure Limited (NASDAQ:NVCR) closed at $75.60 per share on Thursday, up from $69.22 day before. While NovoCure Limited has overperformed by 9.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVCR fell by -26.55%, with highs and lows ranging from $116.56 to $56.39, […]

Source:US Post News
Novocure Secures CE Mark for New Array
Nov 11, 2022 13:00pm

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma. The new arrays are more than 50% thinner and more than 30% lighter compared to current commercial arrays. “Novocure is committed to improving the patient experience and clinical outcomes through innovation, and the new arrays

Source:Business Wire
2 Potentially Explosive Stocks to Buy in November
Nov 08, 2022 10:52am

Both Novocure and MercadoLibre could have good news on the way.

Source:The Motley Fool
NovoCure Limited (NVCR) will benefit from these strategies
Nov 03, 2022 14:00pm

In Wednesday’s session, NovoCure Limited (NASDAQ:NVCR) marked $71.35 per share, down from $73.20 in the previous session. While NovoCure Limited has underperformed by -2.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVCR fell by -33.77%, with highs and lows ranging from $116.56 to $56.39, whereas […]

Source:US Post News
NovoCure''s Return On Capital Employed Insights
Nov 02, 2022 14:19pm

NovoCure (NASDAQ: NVCR ) brought in sales totaling $131.00 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 10.7%, resulting in a loss of $26.58 million. In Q2, NovoCure brought in $140.87 million in sales but lost $24.01 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com

NovoCure: Entering The Next Leaping Growth Phase (NASDAQ:NVCR)
Oct 31, 2022 09:32am

NovoCure is a phenomenal growth stock that recently transitioned into a stalwart. Click here to read the full investment analysis of NVCR stock.

Source:Seeking Alpha
Novocure (NVCR) Q3 2022 Earnings Call Transcript
Oct 27, 2022 20:00pm

NVCR earnings call for the period ending September 30, 2022.

Source:The Motley Fool
NovoCure Ltd. PT Lowered to $42 at Evercore ISI
Oct 27, 2022 17:19pm


NovoCure Limited (NVCR) Q3 2022 Earnings Call Transcript
Oct 27, 2022 15:33pm

NovoCure Limited (NASDAQ:NASDAQ:NVCR) Q3 2022 Earnings Conference Call October 27, 2022 08:00 ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle -…

Source:Seeking Alpha
NovoCure GAAP EPS of -$0.25 beats by $0.03, revenue of $130.99M misses by $2.39M (NASDAQ:NVCR)
Oct 27, 2022 11:11am

NovoCure press release (NVCR): Q3 GAAP EPS of -$0.25 beats by $0.03.Revenue of $130.99M (-2.0% Y/Y) misses by $2.39M.The United States, EMEA and Japan contributed $102.7 million,…

Source:Seeking Alpha
Novocure Reports Third Quarter 2022 Financial Results
Oct 27, 2022 11:09am

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the quarter ended September 30, 2022.

Source:Business Wire
NovoCure Q3 2022 Earnings Preview
Oct 26, 2022 15:48pm

NovoCure (NVCR) is scheduled to announce Q3 earnings results on Thursday, October 27th, before market open.The consensus EPS Estimate is -$0.26 and the consensus Revenue Estimate is…

Source:Seeking Alpha
Why is NovoCure Stock (NASDAQ:NVCR) Down Today?
Oct 24, 2022 16:45pm

Shares of tumor-treating fields devices developer, NovoCure Limited (NASDAQ:NVCR), are down today despite expectations for positive Phase three results for its LUNAR study. The reason for this drop is due to a downgrade from Piper Sandler analyst Jason Bednar, who changed his stance from Buy to Hold. Jason Bednar is concerned about how NovoCure will advance its candidate toward commercialization. As a result, his price target has been lowered to $70 per share from $90 per share. Is NVCR Stock a Good Buy? Overall, NVCR stock has a Moderate Buy consensus rating based on three Buys, one Hold, and one Sell assigned in the past three months.

NVCR stock falls as Piper Sandler downgrades despite positive Phase 3 data (NASDAQ:NVCR)
Oct 24, 2022 15:36pm

NovoCure Limited (NVCR), the developer of tumor treating fields (TTFields) devices to treat cancer, reached a four-month low intraday on Monday after Piper Sandler downgraded the…

Source:Seeking Alpha
Why Novocure Stock Is Sinking Today
Oct 24, 2022 15:16pm

An analyst''s downgrade is weighing on the biotech company.

Source:The Motley Fool
UPDATE: Piper Sandler Downgrades NovoCure Ltd. to Neutral
Oct 24, 2022 10:33am


Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
Oct 21, 2022 22:04pm

Highlights include an analysis of predictive biomarkers for overall survival and progression free survival in newly diagnosed glioblastoma patients Pre-clinical research shows the potential for im…

Source:Finanz Nachrichten
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
Oct 20, 2022 13:21pm

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--A review article of anti-cancer mechanisms of action of Tumor Treating Fields has been published in the Journal of Molecular Cell Biology.

Source:Business Wire
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
Oct 20, 2022 13:16pm

Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an emerging cornerstone of solid tumor treatment. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. With a poor survival outlook across many solid

NovoCure: See Past Market Myopia And Buy The Dip (NASDAQ:NVCR)
Sep 27, 2022 23:30pm

A conservative valuation of NovoCcure''s existing and expected future commercial pipeline suggests strong value accretion ahead. Click here to read more.

Source:Seeking Alpha